Ramucirumab - CISMeF

Preferred Label : Ramucirumab;

NCIt synonyms : Monoclonal Antibody HGS-ETR2; Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B;

NCIt related terms : IMC-1121B;

NCIt definition : A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.;

Alternative definition : NCI-GLOSS: A substance being studied in the treatment of breast cancer that has come back. It binds to receptors for a protein called vascular endothelial growth factor (VEGF). This keeps VEGF from binding to the receptors and may stop the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.;

UNII : D99YVK4L0X;

CAS number : 947687-13-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 947687-13-0 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Cyramza;

Molecule name : IMC-1121B; LY3009806;

Codes from synonyms : CDR0000648687; CDR0000648688; CDR0000648689; 433;

Details

Origin ID

C70792;

UMLS CUI

C2742502;

Automatic exact mappings (from CISMeF team)
- Cyramza [MeSH concept]
CISMeF manual mappings
- Ramucirumab (substance) [SNOMED CT concept]
- ramucirumab [International Nonproprietary Name]
See also inter- (CISMeF)
- Product containing ramucirumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing ramucirumab (medicinal product) [SNOMED CT concept]
- Ramucirumab [Substance BNPC]
- Ramucirumab (substance) [SNOMED CT concept]
- ramucirumab [ATC Code]
- ramucirumab [International Nonproprietary Name]
- ramucirumab [MeSH concept]
Validated automatic mappings to BTNT
- LY3009806 [MeSH concept]
- ramucirumab [ATC Code]
chemical_or_drug_affects_gene_product
- Vascular Endothelial Growth Factor Receptor 2 [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Inhibition of Cell Proliferation [NCIt concept]
- Positive Regulation of Apoptosis [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Vascular Endothelial Growth Factor Receptor 2 [NCIt concept]
is_component_of_chemotherapy_regimen
- Docetaxel/Ramucirumab Regimen [NCIt concept]
- Erlotinib/Ramucirumab Regimen [NCIt concept]
- FOLFIRI-Ramucirumab Regimen [NCIt concept]
- Irinotecan/Ramucirumab Regimen [NCIt concept]
- Paclitaxel/Ramucirumab Regimen [NCIt concept]
- Ramucirumab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients